Lifecore Biomedical (LFCR) Projected to Post Quarterly Earnings on Thursday

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) will likely be releasing its Q2 2026 results after the market closes on Thursday, January 1st. Analysts expect Lifecore Biomedical to post earnings of ($0.11) per share and revenue of $35.3080 million for the quarter. Interested persons can find conference call details on the company's upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, January 2, 2026 at 12:00 AM ET.Get Lifecore Biomedical alerts:Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last posted its quarterly earnings data on Monday, April 1st. The company reported ($0.22) earnings per share (EPS) for the quarter. Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of 25.59%.The company had revenue of $26.54 million for the quarter. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year. Lifecore Biomedical Stock PerformanceNASDAQ:LFCR opened at $8.24 on Thursday. The company has a market capitalization of $308.75 million, a P/E ratio of -7.70 and a beta of 0.60. The business has a fifty day simple moving average of $7.48 and a two-hundred day simple moving average of $7.45. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.80 and a quick ratio of 1.67. Lifecore Biomedical has a 1 year low of $4.76 and a 1 year high of $8.85. Wall Street Analyst Weigh InSeveral equities research analysts have commented on the stock. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Lifecore Biomedical in a report on Wednesday, October 8th. KeyCorp assumed coverage on shares of Lifecore Biomedical in a research note on Wednesday, September 3rd. They issued a "sector weight" rating for the company. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Lifecore Biomedical currently has a consensus rating of "Hold" and an average price target of $6.00.Read Our Latest Report on Lifecore BiomedicalInstitutional Investors Weigh In On Lifecore BiomedicalHedge funds have recently added to or reduced their stakes in the company. Quarry LP bought a new stake in Lifecore Biomedical during the 3rd quarter valued at $28,000. BNP Paribas Financial Markets boosted its stake in Lifecore Biomedical by 92.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company's stock worth $43,000 after purchasing an additional 2,786 shares in the last quarter. State of Wyoming bought a new position in shares of Lifecore Biomedical in the second quarter worth approximately $69,000. The Manufacturers Life Insurance Company purchased a new stake in Lifecore Biomedical during the 2nd quarter valued at $88,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Lifecore Biomedical by 14.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company's stock worth $104,000 after buying an additional 1,886 shares in the last quarter. Institutional investors own 83.36% of the company's stock. Lifecore Biomedical Company Profile (Get Free Report)Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets. The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.Read MoreFive stocks we like better than Lifecore BiomedicalDo not delete, read immediatelyA month before the crashThe McDonald's SecretHow a Family Trust May Be Able To Help Preserve Your WealthWall Street Stockpicker Names #1 Stock of 2026This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Lifecore Biomedical Right Now?Before you consider Lifecore Biomedical, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lifecore Biomedical wasn't on the list.While Lifecore Biomedical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here